Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Rapid Response Innovation Awards, 2010
    Susceptibility Genes for Antipsychotic-induced Extrapyramidal Symptoms as Modifier Genes in Parkinson's Disease and L-dopa Treatment Response

    Objective/Rationale:
    The use of antipsychotic drugs, all of which block dopamine D2 receptors, to treat schizophrenia and other psychotic states is associated with the development of motor acute...

  • Rapid Response Innovation Awards, 2010
    The Role of LRRK2 in Wnt Signaling In Vivo

    Objective/Rationale
    We have preliminary evidence that LRRK2, which is a key protein in Parkinson’s disease (PD), may have a role in an important cellular process called Wnt signaling. Thus it is...

  • Therapeutics Development Initiative, 2010
    Development of an Adult Adherent Allogeneic Stem Cell Product for Treatment of Parkinson's Disease

    Objective/Rationale:
    Previously published data illustrates that MultiStem®, an adult stem cell product approved by the FDA for Phase I studies in humans, works through multiple mechanisms of benefit...

  • Rapid Response Innovation Awards, 2010
    Determine the Structure of Roco Family Proteins

    Objective/Rationale:
    Our aim is the biochemical and structural characterization of the Roco family of proteins. Structures of different Roco constructs will give important insights in the molecular...

  • Pharmacodynamic Biomarkers of LRRK2 Activity, 2010
    Exploiting Ser910/935 Phosphorylation and 14-3-3 Binding to Develop Biomarkers for LRRK2 Activity

    Objective/Rationale: 
    There is great excitement that drugs that target an enzyme termed LRRK2 may have utility for the treatment of Parkinson’s disease. Many companies are attempting to develop LRRK2...

  • Pharmacodynamic Biomarkers of LRRK2 Activity, 2010
    Macrophage Precursors as Biomarker for LRRK2-associated Parkinson disease

    Objective/Rationale: 
    LRRK2 mutations significantly contribute to the development of Parkinson Disease, a multisystem disorder. Neuronal loss is a prerequisite to develop the disease and a crosstalk...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.